{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:11:27Z","timestamp":1792145487845,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix\u00ae software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44\u2009L\/h) and of ivacaftor (9.64 to 11.36\u2009L\/h), indicating a decrease in systemic exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70620","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:21:01Z","timestamp":1779765661000},"page":"3202-3213","source":"Crossref","is-referenced-by-count":1,"title":["Pregnancy\u2010related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7201-3473","authenticated-orcid":false,"given":"Paulette","family":"Magnas","sequence":"first","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-1399","authenticated-orcid":false,"given":"Naim","family":"Bouazza","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Unit\u00e9 de Recherche Clinique Universit\u00e9 Paris Cit\u00e9 Necker\/Cochin, H\u00f4pital Tarnier  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-3404","authenticated-orcid":false,"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Unit\u00e9 de Recherche Clinique Universit\u00e9 Paris Cit\u00e9 Necker\/Cochin, H\u00f4pital Tarnier  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efk","family":"Urien","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique Universit\u00e9 Paris Cit\u00e9 Necker\/Cochin, H\u00f4pital Tarnier  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Froelicher\u2010Bournaud","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Service de Pharmacologie Clinique H\u00f4pital Cochin, AP\u2010HP, Groupe Hospitalier Paris Centre  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"CIC\u20101419 Inserm, H\u00f4pitaux Cochin\u2010Necker  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Guillemart","sequence":"additional","affiliation":[{"name":"CIC\u20101419 Inserm, H\u00f4pitaux Cochin\u2010Necker  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Fesenbeckh","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin, Inserm U1016  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-4742","authenticated-orcid":false,"given":"Jean\u2010Marc","family":"Treluyer","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Unit\u00e9 de Recherche Clinique Universit\u00e9 Paris Cit\u00e9 Necker\/Cochin, H\u00f4pital Tarnier  Paris France"},{"name":"Service de Pharmacologie Clinique H\u00f4pital Cochin, AP\u2010HP, Groupe Hospitalier Paris Centre  Paris France"},{"name":"CIC\u20101419 Inserm, H\u00f4pitaux Cochin\u2010Necker  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis","family":"Tsatsaris","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Maternit\u00e9 Port Royal, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre National de R\u00e9f\u00e9rence de la Mucoviscidose H\u00f4pital Cochin, AP\u2010HP  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin, Inserm U1016  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[{"name":"U1343, Pharmacologie et \u00c9valuations Th\u00e9rapeutiques Chez L'enfant et la Femme Enceinte Inserm, Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"Service de Pharmacologie Clinique H\u00f4pital Cochin, AP\u2010HP, Groupe Hospitalier Paris Centre  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00538-6"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2023.104169"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.024"},{"key":"e_1_2_11_5_1","unstructured":"Cystic Fibrosis Foundation Patient Registry.Annual Data Report 2024.https:\/\/www.cff.org\/medical\u2010professionals\/2024\u2010patient\u2010registry\u2010highlights"},{"key":"e_1_2_11_6_1","unstructured":"Vaincre la mucoviscidose AnatoA KabaK BessouA.Bilan des donn\u00e9es 2023 \u2010Registre fran\u00e7ais de la mucoviscidose. Paris;202415\u201316.https:\/\/www.vaincrelamuco.org\/registredelamuco"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107868"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.006"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404\u2010023\u201006962\u20105"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530261"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116155"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.10.004"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.382"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011\u20104153OC"},{"key":"e_1_2_11_15_1","unstructured":"U. S. Food and Drug Administration.Multi\u2010discipline Review Trikafta 2019 July Report No.: 212273Orig1s000.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_11_16_1","unstructured":"European Medicines Agency.Kaftrio ANNEX 1\u2010Summary of Product Characteristics.20201\u201347.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(24)00249\u20102"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00208-X"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116322"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010025\u201001516\u20101"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030\u2010020\u201000124\u20107"},{"issue":"1","key":"e_1_2_11_22_1","first-page":"S1","article-title":"The concise guide to PHARMACOLOGY 2025\/26","volume":"182","author":"Alexander SPH","year":"2025","journal-title":"Br J Pharmacol"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202102\u20100509OC"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010020\u201009711\u20102"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.09.013"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.05.018"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3705"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp\u20102022\u2010001289"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:38:35Z","timestamp":1787819915000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/bcp.70620"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70620","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}